Search results for " Small"

showing 10 items of 806 documents

Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost–effectiveness analysis

2019

Aim: Osimertinib improves progression-free survival in first-line EGFR mutation–positive non-small-cell lung cancer. Materials & methods: A Markov cohort model including costs, utilities and disutilities, was conducted to estimate quality-adjusted life-year (QALY) and incremental cost–effectiveness ratio when treating with osimertinib versus standard first-line tyrosine kinase inhibitors (TKIs). Results: Osimertinib presented higher QALYs (0.61) compared with standard EGFR–TKIs (0.42). Osimertinib costs were €83,258.99, in comparison with €29,209.45 for the standard EGFR–TKIs. An incremental cost–effectiveness ratio of €273,895.36/QALY was obtained for osimertinib. Conclusion: Osimerti…

Oncologymedicine.medical_specialtyLung NeoplasmsCost effectivenessCost-Benefit AnalysisAntineoplastic Agents03 medical and health scienceschemistry.chemical_compoundEgfr tki0302 clinical medicineCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansOsimertinib030212 general & internal medicineLung cancerProtein Kinase Inhibitorshealth care economics and organizationsAcrylamidesAniline Compoundsbusiness.industryHealth PolicyCost-effectiveness analysismedicine.diseaseMarkov ChainsDacomitinibrespiratory tract diseasesErbB ReceptorsFirst line treatmentchemistry030220 oncology & carcinogenesisMutationQuality-Adjusted Life YearsNon small cellbusinessModels EconometricJournal of Comparative Effectiveness Research
researchProduct

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

2015

Abstract: Background: Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients. Materials and methods: Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (ly-SR), Overall Response Rate (ORR), and grade 3-4 (G3-4) hematologic toxicities. Results: Six eligible trials (741 patients) were selected. Pooled analysis showed a significan…

Oncologymedicine.medical_specialtyLung NeoplasmsPhase iii trialsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPopulationSettore MED/21 - Chirurgia ToracicaNSCLClaw.inventionSingle agentOverall response rateRandomized controlled trialPerformance statuNSCLC; Chemotherapy; Performance status; Platinum; Doublet; Single agentlawCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapyIntensive care medicineeducationRandomized Controlled Trials as TopicPlatinumChemotherapyeducation.field_of_studyPerformance statusbusiness.industryHematologySurvival RateOncologyMeta-analysisDoubletNon small cellHuman medicinePerformance statusbusiness
researchProduct

CD5 and CD6: Evaluation of their role as prognostic biomarkers in resectable non-small cell lung cancer

2018

Oncologymedicine.medical_specialtyOncologybusiness.industryInternal medicinemedicineHematologyNon small cellCD5businessLung cancermedicine.diseaseAnnals of Oncology
researchProduct

Upfront radiation versus EGFR-TKI : which is the best approach for EGFR-mutated NSCLC patients with brain metastasis?

2017

In The Journal of Clinical Oncology , William J. Magnuson (1) and colleagues have recently reported the results of a multicenter retrospective analysis comparing the impact of three different treatment strategies on survival outcomes of 351 patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) and brain metastases (BM). Treatment options included stereotactic radiosurgery (SRS) followed by EGFR-TKI (n=100), whole-brain radiotherapy (WBRT) followed by EGFR-TKI (n=120), or EGFR-TKI followed by SRS or WBRT at the time of intracranial progression (n=131). Results showed a significantly longer median overall survival (OS) in patients who received upfron…

Oncologymedicine.medical_specialtyRadiology Nuclear Medicine and ImagingCancer Researchmedicine.medical_treatmentOncology; Radiology Nuclear Medicine and Imaging; Cancer ResearchRadiosurgeryOncology; Radiology; Nuclear Medicine and Imaging; Cancer ResearchEgfr tkiInternal medicineNuclear Medicine and ImagingmedicineIn patientEpidermal growth factor receptorClinical Oncologybiologybusiness.industrymedicine.diseaserespiratory tract diseasesRadiation therapyOncologybiology.proteinNon small cellHuman medicinebusinessRadiologyBrain metastasisTRANSLATIONAL CANCER RESEARCH
researchProduct

Mortality in early-stage, surgically resected non-small cell lung cancer less than 3cm of size: Competing risk analysis

2015

Abstract Background and objective Survival studies of non-small cell lung cancer (NSCLC) are usually based on the Kaplan–Meier method. However, other factors not covered by this method may modify the observation of the event of interest. There are models of cumulative incidence (CI), that take into account these competing risks, enabling more accurate survival estimates and evaluation of the risk of death from other causes. We aimed to evaluate these models in resected early-stage NSCLC patients. Patients and method This study included 263 patients with resected NSCLC whose diameter was ≤3 cm without node involvement (N0). Demographic, clinical, morphopathological and surgical variables, TN…

Oncologymedicine.medical_specialtyUnivariate analysisMultivariate analysisbusiness.industryCancerCompeting risksmedicine.diseaseSurgeryInternal medicinemedicineCumulative incidenceNon small cellStage (cooking)businessLung cancerMedicina Clínica (English Edition)
researchProduct

Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis

2015

The purpose of this study was to evaluate the clinical value of PET (Positron Emission Tomography) for early prediction of tumor response to platinum-based therapy in patients with nonsmall cell lung cancer (NSCLC). The evaluation was carried out comparing the standard treatment response using RECIST (Response Evaluation Criteria in Solid Tumors) with metabolic treatment response according to European Organization for Research and Treatment of Cancer (EORTC) recommendations, PET Response Criteria in Solid Tumors (PERCIST), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). Seventeen inoperable patients with stage IV NSCLC were enrolled between October 2011 and June 2013: PET st…

Oncologymedicine.medical_specialtybusiness.industryF-FDG PETmedicine.disease18 F-FDG PET EORTC Non-small cell lung cancer PERCIST RECIST Therapy MonitoringPreliminary analysisResponse assessmentEORTCNon-small cell lung cancerRECISTTherapy MonitoringInternal medicinemedicineF-18-FDG PETRadiology Nuclear Medicine and imagingTherapy monitoringRadiologyNon small cellLung cancerbusinessPERCIST
researchProduct

Upregulated Mirna 21 in Kras Mutated Patients is Related to Prognosis in Resectable Non-Small Cell Lung Cancer

2015

Oncologymedicine.medical_specialtybusiness.industryHematologymedicine.diseasemedicine.disease_causeOncologyInternal medicineMutation (genetic algorithm)microRNAmedicineNon small cellKRASbusinessLung cancerAnnals of Oncology
researchProduct

The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lun…

2015

Oncologymedicine.medical_specialtybusiness.industrymedicine.drug_classWild typeHematologymedicine.diseaseTyrosine-kinase inhibitorOncologyThird lineInternal medicinemedicineRetrospective analysisMutational statusNon small cellbusinessLung cancerAnnals of Oncology
researchProduct

Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis

2020

There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. We analyzed overall survival (OS) in the overall cohort, relapse-free survival (RFS) in radically operated patients and progression-free survival (PFS) in patients who received chemotherapy for metastatic disease. Fifty-one BNEC patients were included (male: 46, median age: 70 years). Overall, median OS was 16.0 months, radical tumor resection wa…

Oncologymedicine.medical_specialtymedicine.medical_treatmentNeuroendocrine Carcinoma (NEC)030232 urology & nephrologylcsh:MedicineDiseaseSmall-cell carcinomaArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinedisease-specific survivalStage (cooking)prognostic factorbladdersmall cell carcinomaChemotherapyPerformance statusbusiness.industryPoorly differentiatedlcsh:Rprognostic factorsRetrospective cohort studyGeneral Medicinemedicine.diseaseperioperative chemotherapy030220 oncology & carcinogenesisCohortbusinessbladder; disease-specific survival; neuroendocrine carcinoma (nec); perioperative chemotherapy; prognostic factors; small cell carcinomaJournal of Clinical Medicine
researchProduct

Opportunities and pitfalls related to e-commerce strategies in small-medium firms: A system dynamics approach

2002

E-commerce is often perceived as a powerful lever to foster growth of SMEs. However, both the literature and empirical evidence have shown the perils hidden in superficial decision making by SME entrepreneurs. A system dynamics (SD) approach is used in this article to demonstrate how managing processes of accumulation and depletion of strategic assets, detecting inertial effects of decisions made in the past, and selectively acting on policy levers are likely to help entrepreneurs in understanding opportunities and pitfalls related to e-commerce strategies. A feedback analysis of three case studies selected from the literature and the main findings from a survey conducted by the authors on …

Operations researchbusiness.industryManagement of Technology and InnovationStrategy and ManagementFeedback analysisEconomicse-commerce strategy small–medium firms entrepreneur system dynamicsE-commercebusinessEmpirical evidenceSocial Sciences (miscellaneous)Industrial organizationSystem dynamics
researchProduct